ProMab Biotechnologies

ProMab Biotechnologies, Inc., a subsidiary of Yuan Tai Bio, is mainly engaged in the research and development of innovative antibody technologies. As the first CAR-T CRO service company in the United States, it holds 80% of the U.S. CAR-T CRO service market, providing nearly 400 high-quality services to dozens of large pharmaceutical companies, research centers, and universities worldwide. In addition to customizing CAR-T cells for clients, ProMab has also developed multiple proprietary CAR-T cells based on over 20 years of expertise in monoclonal antibodies. Meanwhile, the company provides off-the-shelf CAR-T cells using its existing antibodies for clients with specific needs and leads related research initiatives. For certain targets, ProMab has successfully developed CAR-NK cells, which show promising prospects as an alternative immunotherapy.